To explain this paradox, we hypothesized that prostate cancer cells might constitutively over-express either IRP1 or IRP2, and that overexpression of these proteins might over-ride the classic iron-mediated iron regulatory pathway to permit high levels of TfR1 and low levels of ferritin in these iron replete cells. The gene discussed is TFRC; the disease is prostate cancer.